SGS to conduct its first malaria human challenge trial in Belgium
![](/46/pdcnewsitem/07/64/14/mosquito-1016254_1280%20(1).jpg)
The advanced candidate compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria.
SGS will commence its first malaria volunteer infection study (VIS) in Belgium in February 2019, on behalf of Medicines for Malaria Venture (MMV), a product development partnership (PDP) working in the field of antimalarial drug research. The study will assist in the development of an advanced candidate compound from the antimalarial drug pipeline developed by MMV and partners, which is a potential long-acting injectable chemoprotective drug.
The primary objective of the trial is to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream, thus protecting people from malarial disease. The trial will be conducted in SGS’ dedicated 20-bed unit at Antwerp’s Stuivenberg Hospital under a high level of safety and supervision.
“SGS is very proud to contribute to the global health effort to defeat malaria in the world. The malaria parasite killed 435,000 people in 2017 and infected an estimated 219 million. Fifty percent of the world’s population are living in over 90 countries where malaria transmission occurs. Ninty-one percent of the deaths are in Africa in predominantly low-income regions. Young children and pregnant women form an especially vulnerable group, associated with a high rate of mortality and as such urgently need novel treatments. This has led to a decision by SGS to step into the field of antimalarial drug development,” commented Adrian Wildfire, Project Director, Infectious Diseases and Human Challenge Unit at SGS.
Dr Pieter-Jan Berghmans, Investigator at SGS and Principal Investigator of the trial, continued: “As there is a continued risk of resistance to currently marketed drugs, developing new antimalarial drugs is a high priority.”
“MMV and its partners have taken a leadership role in finding new ways to accelerate the development of new medicines to treat and prevent malaria. The compound undergoing the trial has demonstrated potential to target malaria parasites before they have a chance to establish the symptoms of malaria, and could therefore help protect children from becoming ill. In collaboration with SGS, this potential treatment will be tested in human subjects for the first time,” said Dr Timothy Wells, MMV’s Chief Scientific Officer.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance